Benefits
Lean mass and muscle size: mixed, unproven
One small manufacturer-connected trial (Joy 2014, 28 trained men) found phosphatidic acid at 750 mg/day plus resistance training produced greater lean body mass gains than placebo (about +2.4 kg over placebo). Two independent trials found no significant difference from placebo in lean mass or muscle size: Gonzalez 2017 at 750 mg/day (15 men) and Andre 2016 at 250 to 375 mg/day (28 men). The lean-mass benefit has not been reproduced independently.
Strength: not reliably shown
The single positive trial (Joy 2014) reported greater leg-press strength gains with PA than placebo; it did not measure squat or bench press. Two independent trials measured squat, bench-press and deadlift 1RM and found no significant difference between PA and placebo (Gonzalez 2017; Andre 2016). A strength benefit has not been reliably demonstrated.
mTOR-mediated muscle protein synthesis
In cell and molecular studies, phosphatidic acid binds mTORC1 (mechanistic target of rapamycin complex 1) and can raise muscle protein synthesis signaling. This is a plausible mechanism, but a signal measured in cells does not by itself prove a muscle-building benefit in people, and the human trials of oral PA have been inconsistent.
Body composition: no fat-loss advantage shown
Trials of phosphatidic acid have not shown a significant reduction in fat mass compared with placebo. Claims of improved body recomposition rest on the lean-mass finding of one small trial and are not supported by the independent trials, which found no body-composition advantage over placebo.
Mechanism of action
Direct mTORC1 activation via PLD pathway
Mechanical stress during resistance exercise activates phospholipase D (PLD), which converts membrane phosphatidylcholine to phosphatidic acid. PA then directly binds the FKBP12-rapamycin binding (FRB) domain of mTOR, activating mTORC1 and triggering ribosomal S6 kinase 1 (S6K1) phosphorylation — the proximal signal for muscle protein synthesis initiation.
Synergy with mechanical muscle loading
PA's anabolic effects require resistance exercise stimulus — it amplifies the mTOR response to mechanical loading rather than activating it independently. This exercise-dependency explains why PA is specifically effective in trained individuals performing progressive resistance training rather than in sedentary populations.
Myofibrillar protein synthesis enhancement
PA-mediated mTORC1 activation specifically enhances myofibrillar (contractile) protein synthesis in type II muscle fibers, increasing the synthesis of myosin heavy chain and actin — the proteins that directly contribute to muscle size and force production.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Mediator® PA (750 mg/day) vs placebo in 28 resistance-trained men + 8-week resistance training program. Outcomes: lean body mass (DXA), squat 1RM. (Joy et al. 2014, Nutr Metab)
28 resistance-trained men. 8-week intervention.
PA group gained more lean body mass (about +2.4 kg over placebo) and showed greater leg-press 1RM improvement vs placebo (the trial measured leg press, not squat). Critical caveat: small trial (n=28), industry-funded (Chemi Nutra); subsequent independent trials have been mixed — some negative. Effects haven't been consistently replicated.
Randomized, double-blind, placebo-controlled trial (Andre et al. 2016, J Sports Sci Med) of PA at 250 mg/day or 375 mg/day vs placebo in 28 resistance-trained men over 8 weeks. Muscle size was measured as rectus femoris cross-sectional area by ultrasound, not MRI.
28 resistance-trained men (9 on 375 mg PA, 9 on 250 mg PA, 10 placebo). 8-week intervention.
Both PA and placebo groups improved in body mass, lean mass, rectus femoris cross-sectional area and lower-body strength, but there were no significant differences between PA and placebo (no group-by-time interaction, p > 0.05). The authors' positive framing relied on magnitude-based inference, a statistical method now widely questioned. By conventional analysis this independent trial was null.